InvestorsHub Logo
Post# of 251938
Next 10
Followers 829
Posts 119690
Boards Moderated 16
Alias Born 09/05/2002

Re: None

Monday, 08/01/2005 9:09:02 AM

Monday, August 01, 2005 9:09:02 AM

Post# of 251938
GTC Biotherapeutics Receives Notice of Allowance on Purification Patent

[Yet another feather in GTC’s IP cap.]

http://biz.yahoo.com/bw/050801/15446.html?.v=1

>>
Monday August 1, 9:00 am ET

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Aug. 1, 2005--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB ) announced today that the United States Patent and Trademark Office has issued a notice of allowance for the claims in its patent application 10/635,117 covering tangential flow filtration technology. These claims provide GTC with a unique position in the use of this technology to recover recombinant therapeutic proteins that are expressed in the milk of transgenic animals. The patent that issues from this application will expire in 2023.

Tangential flow filtration is an initial product recovery step that removes fats and other colloidal proteins such as casein from milk containing the target protein of interest. This approach also allows for the significant reduction in volume of the milk while yielding a material that can be aseptically processed. The resulting partially purified intermediate bulk product is more stable than unprocessed milk and can be stored for extended periods either refrigerated or frozen. The intermediate bulk product is then taken through additional purification steps, typically chromatography, to obtain a highly purified form of the desired therapeutic protein.

GTC is able to produce a therapeutic protein in an animal's milk through a process known as transgenic technology. GTC couples the gene expressing a specific protein with a specific milk protein promoter gene and incorporates it into an animal's genome such that the protein is expressed during lactation. This approach has been demonstrated to enable the production of therapeutic proteins that are difficult to express in traditional production methods. For products that can be expressed in conventional recombinant technology, transgenic technology has significantly lower capital requirements to establish large volume capacity.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.